View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
November 3, 2011

Spine Wave initiates NuCore injectable nucleus device study

Spine Wave has begun a clinical study to determine the feasibility of implanting its NuCore injectable nucleus device using a proprietary percutaneous technique to treat degenerative disc disease.

Spine Wave has begun a clinical study to determine the feasibility of implanting its NuCore injectable nucleus device using a proprietary percutaneous technique to treat degenerative disc disease.

NuCore material consists of rDNA-based protein polymer and a transient radiopacifier, which allows the material to be visualised intra-operatively during percutaneous injection.

The NuCore material will relieve pain, maintain disc height and restore biomechanical function in degenerative disc disease patients.

Dr Ulrich Berlemann of the Spine Center in Thun, Switzerland, said the initial results from an ongoing study involving the device have shown considerable reductions in pain scores within the three month post-operative evaluation.

Spine Wave chairman and CEO Mark LoGuidice said that the study will be an add-on to the previous clinical work, which demonstrated the device’s safety and that it could maintain disc height.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Get important industry news and analysis sent to your inbox
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Hospital Management